The human cytomegalovirus gene products US2 and US11 induce proteasomal degradation of MHC class I heavy chains. We have generated an enhanced green uorescent protein±class I heavy chain (EGFP±HC) chimeric molecule to study its dislocation and degradation in US2-and US11-expressing cells. The EGFP±HC fusion is stable in control cells, but is degraded rapidly in US2-or US11-expressing cells. Proteasome inhibitors induce in a time-dependent manner the accumulation of EGFP±HC molecules in US2-and US11-expressing cells, as assessed biochemically and by cyto¯uorimetry of intact cells. Pulse±chase analysis and subcellular fractionation show that EGFP±HC proteins are dislocated from the endoplasmic reticulum and can be recovered as deglycosylated¯uorescent intermediates in the cytosol. These results raise the possibility that dislocation of glycoproteins from the ER may not require their full unfolding.
Introduction
Misfolded proteins, a consequence of imperfections in protein folding, are unavoidable by-products of protein biosynthesis, regardless of the destination of the translation product (Schubert et al., 2000) . Polypeptides that do not acquire their proper conformation or quaternary structure usually fail to reach their target and are destroyed (Bonifacino and Weissman, 1998) . The endoplasmic reticulum (ER) is the point of insertion of most secretory and membrane proteins and serves as an important station for quality control (Ellgaard et al., 1999) . In the ER, the requirements for protein folding and sensing of the misfolded state are not easily reconciled with the coincident degradation of mis®ts. The distinctions between a nascent polypeptide that has yet to reach its ®nal conformation, and a protein that has exhausted all attempts at proper folding defy a simple description.
In living cells, folding and degradation of ER-inserted proteins are carefully segregated in space. The ER provides an environment that is conducive to protein folding, usually catalyzed by chaperones that include calnexin and calreticulin as well as oxidoreductases such as PDI and ERp57 (Frand et al., 2000; High et al., 2000) .
Proteolysis of unwanted polypeptides is segregated from the folding environment by the ER membrane and can occur in the cytosol. This arrangement requires the transfer of misfolded proteins from the ER to the cytosol, a process known as dislocation or retrograde translocation (Wiertz et al., 1996a) . Based on genetic experiments in yeast and biochemical analysis in mammalian cells, the dislocation reaction is carried out via the translocon or Sec61 complex (Wiertz et al., 1996b; Pilon et al., 1997; Plemper et al., 1997 Plemper et al., , 1998 Bebok et al., 1998; Zhou and Schekman, 1999) . Some lumenal chaperones, such as calnexin, BIP and PDI, have also been implicated in this reaction (McCracken and Brodsky, 1996; Plemper et al., 1997; Gillece et al., 1999; Nishikawa et al., 2001) . In addition, ER membrane proteins as well as cytosolic proteins are involved in the degradation process (Hampton et al., 1996; Hiller et al., 1996; Knop et al., 1996; Biederer et al., 1997; Bordallo et al., 1998; Tiwari and Weissman, 2001; Zhang et al., 2001) . However, most of the proteins in the latter category are associated with ubiquitylation events, usually a necessary step for proteasomal degradation (Hirsch and Ploegh, 2000; Pickart, 2000) .
Virus-infected cells must avoid detection by the immune system if they are to continue to produce infectious virus (Tortorella et al., 2000) . The Herpes viruses are particularly adept at avoiding immune recognition. To achieve temporary invisibility, they have coopted the mechanisms of protein turnover to selectively eliminate major histocompatibility complex (MHC) class I molecules involved in antigen presentation (Tortorella et al., 2000) . The human cytomegalovirus (HCMV)-encoded US2 and US11 proteins accelerate destruction of MHC class I heavy chains (Wiertz et al., 1996a; Huppa and Ploegh, 1997; Tortorella et al., 1998; Shamu et al., 1999) . By conferring speci®city for class I molecules and by accelerating the rate constant of degradation, the HCMV-encoded US2 and US11 proteins manage to selectively reduce the half-life of the class I heavy chains from hours to minutes (Wiertz et al., 1996a,b) . Since the presence of US2 or US11 is suf®cient to observe enhanced degradation, these viral glycoproteins must somehow have adopted the machinery used for turnover of ER proteins. Does removal of glycans, when present, precede extraction or is it con®ned to the cytosol, and is it always catalyzed in the same manner? Is ubiquitin conjugation obligatorily required, and if so, where does this happen, and in what type of linkage is ubiquitin attached (Shamu et al., 1999) ? Is reduction of intra-and inter-chain disul®de bonds a prerequisite for dislocation (Tortorella et al., 1998) ? Can folded proteins be extracted, or is complete unfolding required? The answers to these questions will require a detailed analysis of a number of substrates susceptible to this mode of degradation.
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Here we used an enhanced green¯uorescent protein± class I heavy chain fusion (EGFP±HC) as a model protein to study US2-and US11-mediated dislocation and degradation. Characterization of EGFP±HC expressed in control U373-MG cells that do not express US2 or US11 shows that this reporter construct largely behaves like its endogenous counterpart. We show that the chimeric molecules and the endogenous class I heavy chains are dislocated and degraded in a similar manner in the presence of HCMV US2 and US11. Fluorescence microscopy and spectroscopy data are consistent with the possibility that dislocation does not require complete unfolding of the dislocation substrate.
Results
The EGFP±HC chimeric molecule is inserted into the membrane and folds properly In the course of US2-/US11-induced class I degradation, ER-resident class I molecules are dislocated into the cytosol for degradation by the proteasome. To visualize the dislocation of class I molecules in US2-and US11-expressing cells, we generated a reporter construct comprised of an N-terminal signal sequence, followed by the EGFP moiety fused to the N-terminus of the HLA-A2 heavy chain (EGFP±HC). Because GFP is a stable molecule with a compact tertiary structure, the¯uorescent properties of this reporter should be helpful in addressing the unfolding requirements of the EFGP/HC chimera prior to degradation.
For a simple GFP fusion protein, folding is inferred from the emergence of green¯uorescence. In the case of the EGFP±HC fusion protein, we may use as an additional criterion the acquisition of the W6/32 antibody epitope, present on properly folded class I molecules only. We ®rst examined the biosynthesis of EGFP±HC in a pulse±chase experiment in U373-MG cells stably transfected with EGFP±HC (U373 EGFP±HC ) (Figure 1 ). U373 EGFP±HC cells were metabolically labeled for 15 min and chased up to 90 min. The product encoded by the EGFP±HC fusion construct was directed to the ER by the H2-K b signal sequence fused to the N-terminus of the chimera. The ability of the fusion protein to fold and associate with b 2 -microglobulin (b 2 m) was assessed by its reactivity with the monoclonal antibody, W6/32 (Figure 1, lanes 1±6 ). Both the fusion protein and the endogenous MHC class I molecules acquired the W6/32 epitope, indicative of correct folding and assembly, although the EGFP±HC is less effective at acquiring the W6/32 epitope.
Does the EGFP±HC traf®c to the cell surface? We ®rst addressed biochemically whether the EGFP±HC molecules exit the ER. We found that a population of EGFP±HC molecules and endogenous class I molecules that were precipitated with W6/32 are resistant to endoglycosidase H (Endo H) treatment (Figure 1 , lanes 4±6). Resistance to Endo H is indicative of N-linked glycan modi®cations that occur in the Golgi. Therefore, the EGFP±HC molecules that associate with b 2 m can exit the ER although we have not determined whether EGFP±HC travels to the surface as ef®ciently as its endogenous counterpart. We conclude that a signi®cant population of EGFP±HC molecules is properly folded. For the remainder of our experiments, we focus on the events in the ER and cytosol.
Fluorescence microscopy was used to further analyze the distribution of the fusion protein in intact cells. The localization of the green¯uorescent species, EGFP±HC, relative to the red staining pattern derived from W6/32, shows properly folded EGFP±HC at the cell surface and intracellularly, presumably in the ER (Figure 2A ). Partial ER localization of EGFP±HC was con®rmed by staining with antibodies against ER markers calnexin ( Figure 2B ) and PDI ( Figure 2C ). These results establish that the EGFP±HC is found throughout the secretory pathway and at the cell surface.
The EGFP±HC fusion molecule is a substrate for US2-and US11-mediated degradation Is the EGFP±HC fusion molecule a substrate for the HCMV-encoded US2 and US11 proteins? We generated stable cotransfectants of EGFP±HC and US2 or US11 in U373-MG cells (US2 EGFP±HC and US11 EGFP±HC ). The levels of expression of EGFP±HC, as assessed by pulse labeling, were similar to those in U373 EGFP±HC cells. The fate of EGFP±HC in both cell lines was examined by pulse±chase analysis (Figure 3 ). The EGFP±HC molecules were recovered from SDS-treated cell lysates using a polyclonal anti-GFP serum (aGFP). The class I heavy chains were recovered using a polyclonal anti-heavy chain serum (aHC) that recognizes unfolded class I heavy chains. The immunoprecipitates were then analyzed by SDS±PAGE. Only in US2 EGFP±HC and US11 EGFP±HC cells did we observe a rapid loss of EGFP±HC and endogenous HC over the chase period ( Figure 3A , lanes 4±9). These results are consistent with degradation of class I induced by US2 or US11 (Tortorella et al., 1998) . Given the structural information available for the class I±US2 complex, we suggest that the ability of the EGFP±HC fusion to be degraded in a US2-dependent manner is further evidence of a correctly folded state for EGFP±HC (Gewurz et al., 2001a) . Even though EGFP±HC and endogenous HC molecules are degraded with similar kinetics in US2 EGFP±HC and US11 EGFP±HC cells ( Figure 3B ), different amounts of endogenous HC are recovered at the 0 chase period ( Figure 3A , compare lanes 13 and 16). This suggests that the presence of EGFP±HC molecules in US2 cells affects the kinetics of class I degradation, and slows degradation of endogenous class I heavy chains.
A pulse±chase analysis of EGFP±HC in US2 EGFP±HC and US11 EGFP±HC cells was then conducted in the presence of the proteasome inhibitor, ZL 3 VS. The EGFP±HC and endogenous heavy chains were recovered from cell lysates using aHC serum (Figure 4) . A precursor±product relationship between the EGFP±HC molecule and a faster moving polypeptide was observed during the chase period ( Figure 4A , lanes 1±6). This intermediate is absent from cells not exposed to proteasome inhibitors (Figure 3) . The presence of a biosynthetic intermediate of reduced molecular weight is consistent with the loss of the single N-linked glycan ( Figure 4A , lanes 7±9) present in both the endogenous class I heavy chains and the fusion product. Indeed, the intermediate is resistant to digestion with puri®ed N-glycanase. The deglycosylated intermediate is thus the product of an N-glycanase reaction, as con®rmed by an isoelectric focusing experiment (Wiertz et al., 1996a ; data not shown). The rate of appearance of the deglycosylated EGFP±HC intermediates in pulse±chase experiments was only moderately delayed when compared with the endogenous class I heavy chain intermediates. The presence of a compact folded EGFP moiety is likely to effect the rate of discharge of the fusion protein from the ER. In the presence of the proteasome inhibitor, minor quantities of additional polypeptides were detected over the course of the chase period (* and **, Figure 4A ). Subcellular fractionation followed by immunoprecipitation shows that these polypeptides are cytosolic ( Figure 4B ). The slower migrating polypeptide (*) ( Figure 4A ) reacts with both aHC and aGFP, while the faster migrating polypeptide (**) ( Figure 4A ) reacts only with aHC (data not shown). Therefore, these fragments correspond to heavy chain-derived digestion products generated from cytosolic deglycosylated intermediates. At steady state, these products are not detectable ( Figure 4C ).
In keeping with our earlier observations on the endogenous MHC class I products, the deglycosylated fusion product fractionated with the cytosolic compartment, unlike the transferrin receptor analyzed in the same experiment ( Figure 4B ). The transferrin receptor was recovered quantitatively in the particulate fraction obtained by differential centrifugation, whereas the deglycosylated MHC class I intermediate remained soluble ( Figure 4B , lanes 4±6). We conclude that the EGFP±HC Fig. 2 . Intracellular distribution of EGFP±HC is similar to that of endogenous class I molecules. U373 EGFP±HC were grown on chamber slides over night, prior to ®xation, immunohistochemistry and confocal laser scanning microscopy. Double-positivity of the green¯uorescent EGFP±HC molecule with W6/32 corresponds to properly folded class I complexes that contain the chimeric molecule. These are found at the cell surface (A) and in the ER. ER localization of EGFP±HC is demonstrated by staining with the ER markers calnexin (mAb AF8) (B) and PDI (anti-PDI) (C). For each antibody the green EGFP±HC (left column), the respective second staining in red (middle column) and a merge image (right column) are shown, as indicated for the individual panels.
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fusion protein behaves like the endogenous class I heavy chain as far as US2 and US11-mediated dislocation and degradation are concerned.
Steady-state expression levels of EGFP±HC in U373 EGFP±HC and US11 EGFP±HC cells were analyzed by aGFP western blots ( Figure 4C ). Lysates prepared in SDS from equal numbers of untreated ( Figure 4C , lanes 1 and 2) and ZL 3 VS-treated ( Figure 4C , lanes 3 and 4) cells were subjected to SDS±PAGE and immunoblotting. U373 EGFP±HC cells ( Figure 4C , lanes 1 and 3) express equivalent levels of EGFP±HC, independent of the presence of the proteasome inhibitor. In contrast, EGFP±HC is barely detectable in untreated US11 EGFP±HC cells ( Figure 4C , lane 2), but appears as the deglycosylated intermediate when proteasomal degradation is inhibited ( Figure 4C , lane 4). No other aGFP-reactive degradation products were detected at steady state, in agreement with the results from pulse±chase experiments.
Time-dependent accumulation of EGFP±HC in US2 EGFP±HC and US11 EGFP±HC upon inhibition of proteasomal degradation We used the EGFP±HC reporter in FACS analysis, uorimetric emission analysis and¯uorescence microscopy experiments to explore the dislocation reaction in intact cells. Co-expression of either US2 or US11 with EGFP±HC essentially abolished all¯uorescence, a further indication of the ability of the fusion protein to serve as a substrate for US11/US2-mediated degradation ( Figure 5A ). We quanti®ed the appearance of green¯uorescence EGFP±HC in US2 EGFP±HC and US11 EGFP±HC cells by FACS analysis when proteasome activity is blocked. Treatment of the cells with ZL 3 VS induces the accumulation of EGFP±HC in a time-dependent manner in US2 EGFP±HC and US11 EGFP±HC cells, with the half-maximal value attained after~1 h ( Figure 5A ). Untransfected U373-MG cells did not show any¯uorescence accumulation ( Figure 5A ). In the absence of US11 and US2, the levels of EGFP±HC fusion increased only slightly upon proteasomal inhibition ( Figure 5A ). These results were corroborated using¯uorimetric emission analysis of NP-40 lysates from U373-MG, U373 EGFP±HC and US11 EGFP±HC cells ( Figure 5B ). The EGFP¯uorescence from lysates of US11 EGFP±HC cells was signi®cantly greater when cells had been treated with the proteasome inhibitor, ZL 3 VS. As expected, there was no signi®cant difference in the EGFP¯uorescent observed from lysates of ZL 3 VS treated and non-treated U373 EGFP±HC cells.
Next, we examined the intracellular localization of ZL 3 VS-induced EGFP±HC by¯uorescence microscopy in ®xed cells. Cells grown on glass cover slips were pretreated with ZL 3 VS for 3±5 h prior to immunohistochemistry. In US11 EGFP±HC cells, we observed co-localization of green¯uorescence with W6/32 ( Figure 5C ) or HC10 ( Figure 5C ) reactive material. Co-localization of EGFP±HC with W6/32 reactive material shows that properly formed class I complexes include the EGFP±HC fusion protein. A small population of W6/32 reactive EGFP±HC can be observed at the cell surface ( Figure 5C ). However, this co-distribution is substantially less than that seen for EGFP±HC and HC10 ( Figure 5C , compare the ®rst two rows). EGFP±HC co-localizes perfectly with HC10, a monoclonal anti-class I reagent that reacts with free (unfolded) class I heavy chains (Stam et al., 1986) . Direct examination of EGFP species with anti-GFP serum (Seedorf et al., 1999) , does not show a signi®cant population of non-folded, non-¯uorescent EGFP±HC molecules ( Figure 5C , bottom row). Similar results were obtained when these experiments were performed in US2 EGFP±HC cells (data not shown). We conclude that the green¯uorescent signal observed in our cells is indeed derived from EGFP±HC chimeric molecules, fully consistent with the result from the biochemical analysis (Figure 3 ).
Cytosolic EGFP±HC does not form aggresomes Cells respond to the production of high levels of certain misfolded protein by transport of the aggregated material to a perinuclear inclusion region and the formation of structures referred to as aggresomes (Johnston et al., 1998) . Formation of these inclusion bodies was initially described for the cystic ®brosis transmembrane conductance regulator (CFTR) (Johnston et al., 1998) , presenilin (Wigley et al., 1999) and a GFP-fusion protein (GarciaMata et al., 1999) as a general cellular response to misfolded unassembled proteins. Aggresomes presumably result when cytoplasmic degradation cannot clear the misfolded material in a timely manner. Does inhibition of proteasomal degradation induce such cytosolic structures for EGFP±HC? Aggresomes have been de®ned by their location close to the centrosome and an attendant redistribution of the intermediate ®lament protein vimentin into a halo-like cage around the aggregated proteins. Antivimentin immunostaining was performed on U373 EGFP±HC and US11 EGFP±HC cells (Figure 6 ). Vimentin ®laments of U373 EGFP±HC cells ( Figure 6A ) were compared with the ZL 3 VS-treated US11 EGFP±HC cells ( Figure 6B ). No difference in the distribution of vimentin was apparent. The presence of US11 did not affect the vimentin pattern as compared with control cells, regardless of the inclusion of proteasome inhibitors. Vimentin distribution was equally unaffected by ZL 3 VS treatment of U373 EGFP±HC cells (data not shown). Similar results were observed with US2 EGFP±HC cells. Furthermore, some of the perinuclear EGFP±HC must be ER-resident ( Figure 2 , middle row; Figure 7A ). The lack of clearly de®ned vimentin cages and the broad distribution of the accumulated EGFP±HC in proteasome inhibitor-treated cells argues against the presence of aggresomes in our experimental model (Kopito, 2000) .
Visualization of EGFP±HC dislocation
Direct visualization of the dislocation of proteins in live cells has not been possible so far. We used the Fig. 4 . EGFP±HC is dislocated from the ER into the cytosol. (A) US11 EGFP±HC and US2 EGFP±HC cells were pulse-labeled with [ 35 S]methionine for 15 min and chased up to 90 min in the presence of the proteasome inhibitor, ZL 3 VS. Cells were lysed in 1% SDS, then diluted to 0.07% SDS with NP-40 lysis mix followed by immunoprecipitation with anti-class I heavy chain serum (aHC). The immunoprecipitates were analyzed by SDS±PAGE (12.5%). The EGFP±HC (lanes 1±9) and endogenous class I molecules (HC) (lanes 10±15) were recovered from US2 EGFP±HC and US11 EGFP±HC cell lysates. Some class I degradation intermediates (* and **) were present in the US2 and US11 cell lysates. Half of the immunoprecipitates from US11 cells were digested with N-glycanase (PNGase) (lanes 7±9 and 16±18). (B) US11 EGFP±HC cells were pulse-labeled with [ 35 S]methionine for 15 min and chased up to 90 min in the presence of the proteasome inhibitor, ZL 3 VS. Cells were homogenized and subjected to fractionation as described in Materials and methods. The EGFP±HC, endogenous HC (aHC; lanes 1±9) and transferrin receptor (aTfr; lanes 10±18), were recovered from the whole-cell lysate (Whole Cell), from the 100 000 g supernatant (100Kg-sup) and the 100 000 g pellet (100Kg-pellet). The immunoprecipitates were analyzed by SDS±PAGE (12.5%). (C) Steady-state levels of EGFP±HC in U373 EGFP±HC and US11 EGFP±HC cells. Immunoblots of SDS lysates from equal numbers of untreated (lanes 1 and 2) and ZL 3 VS-treated (3 h; 50 mM; lanes 3 and 4) cells (0.25 Q 10 6 ) were performed with a polyclonal anti-GFP serum. U373 EGFP±HC cells (lanes 1 and 3) express equal levels of EGFP±HC, independent of the proteasome inhibitor treatment. Inhibition of proteasomal degradation results in accumulation of EGFP±HC in US11 EGFP±HC cells (lanes 2 and 4) mostly as the deglycosylated intermediate. Molecular weight markers are indicated on the left in kDa.
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EGFP±HC fusion to address two types of question. First, where exactly do cells accumulate EGFP±HC induced by inhibition of proteasomal degradation? Secondly, can we follow the fate of a distinct EGFP±HC subpopulation within a cell? We ®rst examined the intracellular distribution of the EGFP±HC in detail by confocal laser scanning microscopy. US11 EGFP±HC cells treated with ZL 3 VS were stained for the ER markers concanavalin A ( Figure 7A , top row), calnexin ( Figure 7A , middle row) and PDI ( Figure 7A , bottom row) to identify the ERresident fraction of EGFP±HC. In both US11 EGFP±HC and US2 EGFP±HC (data not shown) cells, a signi®cant population of EGFP±HC co-localizes with these ER markers ( Figure 7A ), demonstrating that properly folded¯uores-cent EGFP±HC molecules are detected in the ER.
We next designed an experiment that would allow the accumulation of EGFP±HC in the ER by blockade of proteasomal proteolysis, followed by removal of inhibition Immunostaining followed by confocal laser scanning microscopy was carried out as described in Materials and methods. For each antibody the green EGFP±HC (left column), the respective second staining in red (middle column) and a merge image (right column) are shown, as indicated for the individual panels. Double-positivity of EGFP±HC with W6/32 shows the localization and the co-localization of properly folded class I complexes and their presence at the cell surface (top row). Almost complete co-localization of EGFP±HC with HC10, the monoclonal antibody reactive with class I independent of its folding, shows that this¯uorescence is indeed derived from a green class I fusion protein (middle row). Staining with the aGFP reagent depicts no additive GFP-tagged population that for some reason (unfolding) failed to acquire green¯uorescence (anti-GFP; bottom row).
and ensuing dislocation and degradation of EGFP±HC. For this purpose we used the reversible inhibitor ZL 3 -aldehyde (MG132) (Lee and Goldberg, 1996) : proteasomal activity resumes upon removal of the inhibitor. By blocking de novo protein synthesis by the addition of cycloheximide (CHX), the egress of the pre-existing, ER-localized population of EGFP±HC can be followed during the dislocation process without the confounding effect of its de novo synthesis.
In Figure 7B (top row), EGFP±HC molecules colocalized with ER markers in MG132-treated US11 EGFP±HC cells are represented as yellow pixels. This yellow signal corresponds to the merged image of the green EGFP±HC and in red the ER staining with concanavalin A, anticalnexin antibody or anti-PDI antiserum, respectively ( Figure 7B ). The fraction of immunostaining that does not colocalize is rendered on a gray scale. Examination of US11 EGFP±HC cells 1.5 h after the addition of CHX sharply reduces colocalization in cells stained with the respective ER markers ( Figure 7B , lower panels). This implies that the initially ER-localized population of EGFP±HC has now left the ER. Likewise, co-localization of W6/32 and EGFP±HC is no longer observed in ER compartments of such treated cells (data not shown). These results demonstrate that a properly folded¯uorescent EGFP±HC species can be targeted for dislocation and subsequent degradation in an US11-dependent manner.
To examine the degradation kinetics of¯uorescent EGFP±HC molecules, we stopped the degradation of EGFP±HC in US11 EGFP±HC cells by blocking proteasomal function with MG132 for 3 h ( Figure 8A) . The inhibitor was then removed and the mean¯uorescence intensity of accumulated EGFP±HC was monitored over a 3 h time period in the presence of the protein synthesis inhibitor CHX. FACS analysis shows that the initial accumulation of green¯uorescence is comparable to that seen in cells treated with the irreversible inhibitor ZL 3 VS ( Figure 5A ). Within 3 h after the washout of the proteasome inhibitor, this accumulation phase is followed by a decline of signal to background levels ( Figure 8A ). CHX treatment of cells that did not express US11 failed to show this rapid loss of green¯uorescence ( Figure 8A ). Similar results were obtained from US2 EGFP±HC cells (data not shown). Judged from the decay of EGFP signal in FACS analysis, we determined that a period of 1 h after imposition of the CHX block was optimal to obtain samples for subcellular fractionation and¯uorimetric emission analysis of the cytosolic fractions. We detected¯uorescent EGFP±HC molecules in the cytosol of ZL 3 VS-treated US11 EGFP±HC cells and US2 EGFP±HC cells ( Figure 8B ). After a 1 h CHX chase, there was an increase in recovery of cytosolic uorescent EGFP±HC molecules. In the absence of proteasome inhibitor, US2 EGFP±HC and US11 EGFP±HC cells showed very little¯uorescence in their cytosolic fractions (data not shown). We conclude that EGFP±HC molecules can exist in the cytosol as¯uorescent species and accumulate if dislocation is allowed to proceed in the presence of proteasome inhibitor. EGFP¯uorescence implies a properly folded state at least for the EGFP moiety. This raises the question whether EGFP±HC needs to unfold for dislocation to proceed, and if so, whether an unfolded EGFP±HC molecule could re-acquire¯uorescent properties.
Hysteresis in unfolding of EGFP±HC and EGFP molecules
We addressed the stability of EGFP±HC chimeric molecules by examining in vitro their¯uorescent properties in the presence of a denaturant. All¯uorescence of EGFP±HC molecules from U373 EGFP±HC cells, ZL 3 VStreated US2 EGFP±HC and ZL 3 VS-treated US11 EGFP±HC cells is extinguished in a guanidine hydrochloride (GuHCl)-concentration dependent manner ( Figure 8C ). The EGFP±HC molecules are denatured at similar concentrations of GuHCl as free, cytosolic EGFP molecules in U373-MG cells (U373 EGFP ) ( Figure 8C ).
Can an unfolded EGFP±HC chimera refold into a¯uorescent species? EGFP±HC molecules from U373 EGFP±HC cells denatured by addition of 5.0 M GuHCl ( Figure 8D ; open square) do not re-acquire green uorescence upon dilution to 0.3 M GuHCl (closed square) ( Figure 8D ). In contrast, when cytosolically expressed, free EGFP molecules were subjected to the same treatment [5.0 M GuHCl (open circle) to 0.3 M Fig. 6 . Inhibition of proteasomal degradation in US11 EGFP±HC cells does not induce the formation of aggresomes. Immunostaining with anti-vimentin mAb V9 and confocal laser scanning microscopy was performed to study the distribution of vimentin ®laments in untreated U373 EGFP±HC cells (A) and US11 EGFP±HC cells treated with ZL 3 VS (50 mM; 3 h) (B). No signi®cant difference between the vimentin distribution was detected for either cell type. The green EGFP±HC (left column), the anti-vimentin staining in red (middle column) and a merge image (right column) are shown for each panel.
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GuHCl (closed circle)], recovery of EGFP¯uorescence was essentially complete ( Figure 8D ). The EGFP moiety itself can thus refold into a¯uorescent species after denaturation, in agreement with published data (Battistutta et al., 2000; Fukuda et al., 2000) . Taken together, the results imply that the¯uorescent EGFP±HC molecules detected in the cytosol do not necessarily arise from an unfolded cytosolic EGFP±HC species that refolds and requires¯uorescent properties, but instead may originate from EGFP±HC molecules dislocated in a¯uorescent state.
Discussion
To investigate ER dislocation and proteasomal degradation, we use a reporter protein composed of an EGFPmoiety fused at its C-terminus to the HLA-A2 heavy chain (EGFP±HC) preceded by a cleavable N-terminal signal sequence. We show that this protein folds properly, as assessed by the acquisition of the appropriate antibody epitopes and the display of green¯uorescence. Furthermore, we demonstrate that the EGFP±HC, like endogenous class I heavy chains, is readily recognized by the US2 and US11 proteins. This interaction leads to degradation of the fusion protein, a reaction accompanied by the accumulation of the diagnostic deglycosylation intermediate when proteasomal proteolysis is inhibited, both in pulse±chase analysis and at steady state. In addition to endogenous class I heavy chains, the only intermediate(s) of the breakdown reaction are the cytosolic deglycosylated forms of the EGFP±HC. Cytochemical and biochemical analysis at steady state failed to reveal the presence of obvious cleavage products or of a free EGFPmoiety that could have confounded further morphological analysis.
Examination of EGFP±HC in US11 EGFP±HC and US2 EGFP±HC by¯uorescence microscopy showed an almost complete lack of¯uorescence, unless proteolysis was inhibited by the proteasome inhibitors ZL 3 VS or MG132. Block of degradation with either proteasomal inhibitor results in the accumulation of the dislocation substrate. This accumulation is not con®ned only to the cytosol, but extends to the ER as well. We interpret the latter result as the consequence of feedback inhibition: the accumulation of an intermediate in the cytosol affects the reaction(s) immediately upstream, which include(s) the removal from the ER (dislocation) itself. This accumulation is reversible once proteasome inhibitors are removed. When degradation resumes, extraction of¯uorescent material formerly arrested in the ER can now occur. This is best visualized when de novo protein synthesis is blocked, and no new material is inserted into the ER. In 
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other words, EGFP±HC is inserted into the ER where it folds, but can still be effectively dislocated thereafter and degraded by proteasomes.
Vimentin ®laments do not collapse upon cytosolic accumulation of EGFP±HC in US11 EGFP±HC and US2 EGFP±HC cells. This ®nding, in combination with the broad distribution of green¯uorescence throughout the cell, argues against the formation of aggresomes for the EGFP±HC substrate, de®ned as inclusion bodies surrounded by a vimentin cage (Garcia-Mata et al., 1999; Kopito, 2000) . Furthermore, EGFP±HC accumulation is reversible and EGFP±HC remains in a cellular compartment that is readily extractable with NP-40 (this work). The formation of aggresomes, as pointed out by Kopito (2000) , might be a highly substrate-and cell type-speci®c process, with certain cell types more prone to aggresome formation than others. Likewise, the type I membrane protein EGFP±HC might behave differently when compared with multi membrane-spanning proteins, such as CFTR or presenilin (12 and eight transmembrane domains, respectively), commonly used to document aggresome formation (Johnston et al., 1998) .
How is EGFP±HC dislocated from the ER into the cytosol in a manner consistent with its¯uorescent properties in both the ER and the cytosol? As the ®rst of two possible scenarios we propose the following: the ERresident EGFP±HC molecule is initially denatured by ER chaperones, followed by its dislocation into the cytosol as a completely or partially unfolded molecule. We have observed that the disul®de bonds that stabilize the conformation of class I heavy chains are reduced prior to loss of the single N-linked glycan, brought about by the action of a cytosolic N-glycanase (Tortorella et al., 1998) . A catalyst speci®cally involved in this redox reaction remains to be identi®ed, and perhaps is not even required when a disul®de-bonded protein reaches the cytosol. In the presence of proteasome inhibitors, the EGFP±HC molecule would then refold partially to accumulate as a deglycosylated,¯uorescent species. In other words, the folded EGFP±HC molecule would unfold in the ER and at least the EGFP moiety refold in the cytosol. What detracts from this possibility is the fact that the GFP molecule is rather resistant to denaturation. In addition, only in the presence of 6 M GuHCl, but not 6 M urea, is GFP denatured and loses its¯uorescent properties (Weber-Ban et al., 1999) . Complete unfolding of the EGFP±HC molecule also requires a high concentration of GuHCl (5.0 M) ( Figure 8C) . A fully unfolded free EGFP molecule can refold in vitro upon the removal of the denaturants, as judged by the re-emergence of¯uorescent properties of GFP ( Figure 8D ) (Battistutta et al., 2000) , but the EGFP±HC fusion does not ( Figure 8D) . The extent to which such unfolding occurs in living cells is not easily assessed. However, the in vitro renaturation of partially or completely unfolded EGFP±HC molecules to a¯uorescent species was not observed upon dilution of denaturant ( Figure 8D) . Clearly, the attachment of the class I moiety affects the folding properties of EGFP in the fusion protein: free EGFP refolds upon removal of denaturant, whereas EGFP fused to the HC does not. We suggest that in living cells the refolding of the unfolded EGFP±HC fusion protein might be likewise compromised. If correct, our data would be consistent with dislocation of EGFP±HC reporter in a conformation that retains at least the fold for¯uorescent EGFP. In the presence of the ClpA unfoldase,¯uorescent GFP is unfolded in vitro but only if equipped with a degradation signal (Weber-Ban et al., 1999) . A 20% decrease in GFP¯uorescence was observed in the presence of ClpA. It could be argued that the attached heavy chain moiety is in fact a degradation signal for EGFP±HC that acts in a manner similar to the ssrA sequence used to target GFP to the ClpA unfoldase (Weber-Ban et al., 1999) . However, the fact remains that the ubiquitin conjugation apparatus and the proteasome cannot access the EGFP±HC protein until it is exposed to the cytosol.
An additional complication of a model that requires unfolding of the EGFP±HC complex prior to dislocation is the following: the three-dimensional structure of the US2±class I complex has been determined for the lumenal domains (Gewurz et al., 2001a) . This complex is quite stable and survives native gel electrophoresis, as well as several chromatography steps used in the puri®cation of the complex (Gewurz et al., 2001b) . If unfolding were a prerequisite for dislocation, the unfolding reaction would presumably occur in the same compartment where the complex between US2 and US11 was formed in the ®rst place, the ER. The remarkable ef®cacy of the entire dislocation process, perhaps not more than 2 min between completion of the polypeptide chain and the dislocation event (Wiertz et al., 1996a,b) , raises important questions as to the nature of this presumed unfolding and the catalysts involved, given the stability of the US2±class I complex. In summary, one model consistent with our data postulates unfolding immediately prior to escape of EGFP±HC from the ER, followed by re-acquisition of uorescent properties of the EGFP moiety upon arrival in the cytosol. The inhibition of the proteasome is essential for this reaction to yield EGFP±HC in detectable amounts.
An alternative model for dislocation of the EGFP±HC molecule through the ER membrane is that it is dislocated as a folded structure, a suggestion not entirely without precedent and perhaps more consistent with the remarkable stability of the US2±class I complex. Nonetheless, we cannot formally exclude the possibility that the unfolded GFP moiety attached to the class I heavy chain may refold upon arrival in the cytosol. However, we note the following examples that may serve as precedents for the transport of folded molecules across a membrane. Unfolding of cytosolic peroxisomal precursor proteins is not required for import into the peroxisome (Subramani et al., 2000) . Cytosolic proteins stabilized by crosslinking or by pharmacological means were ef®ciently translocated into peroxisomes and glycosomes respectively (Walton et al., 1995; Hausler et al., 1996) . In fact, multimeric proteins are also transported into the peroxisomal matrix. In yeast, a trimer of chloramphenicol acetyltransferase containing a peroxisomal targeting sequence as well as a dimer of peroxisomal thiolase are imported into peroxisomes as oligomeric complexes (Glover et al., 1994; McNew and Goodman, 1994) . Such import sets a precedent for the ability of folded or even multimeric proteins to cross membranes when assisted by the appropriate partners. In view of the shared ancestry of the peroxisomal membrane and the ER (Titorenko and Rachubinski, 2001) , the requirement for unfolding, in contrast to the transport of a multimeric protein complex, is an issue that deserves further study in the context of the dislocation reaction. If transport of a multimeric protein complex across the peroxisomal membrane is possible (Smith and Schnell, 2001) , there is in principle no reason why such transport should be denied to proteins destined to leave the ER for the cytosol.
The Sec61 complex is believed to be the conduit via which proteins are dislocated from the ER. The inner diameter of the translocon pore has been estimated tō uctuate between 15 A Ê in its inactive state (Menetret et al., 2000; Beckmann et al., 2001) to 40±60 A Ê during protein translocation (Johnson and van Waes, 1999) . Can GFP pass through the pore of the Sec61 complex as a folded molecule? GFP is a cylinder 42 A Ê long with a diameter of 24 A Ê (Ormo et al., 1996) . The estimated pore size of the translocon during its active state could therefore allow the passage of the folded GFP molecule. Even if the pore size of the translocon is maximally 60 A Ê when fully active, further rearrangements of the translocon subunits could produce different results. Relatively modest adjustments in the angle of connexin subunits within the membrane can create a completely closed or an open state for gap junctions (Simon and Goodenough, 1998) . In a similar event, re-arrangements of translocon subunits or an adjustment of their stoichiometry initiated from within the ER could modulate pore size.
Materials and methods
Cell lines and antibodies U373-MG astrocytoma cells transfected with the US2 or US11 cDNA were prepared as described Kim et al., 1995) , cells were maintained in DME medium as described (Rehm et al., 2001) . EGFP±HC (U373 EGFP±HC ), US2-EGFP±HC (US2 EGFP±HC ), US11-EGFP±HC (US11 EGFP±HC ) and EGFP (U373 EGFP ) cells were maintained in DME medium supplemented with 5% FCS, 5% calf serum and 0.5 mg/ ml of Geneticin (Gibco, Fredrick, MD). The aHC serum was generated by immunizing rabbits with the bacterially expressed lumenal fragment of HLA-A2 and HLA-B27 heavy chain (Tortorella et al., 1998) . aGFP was generated by immunizing rabbits with the bacterially expressed GFP (Seedorf et al., 1999) . mAbs AF8 (Schreiber et al., 1994) , HC10 (Stam et al., 1986) , W6/32 (Parham et al., 1979) and anti-transferrin receptor (van de Rijn et al., 1983) were used as described. Anti-vimentin mAb V9 (Sigma, St Louis, MO) was used for the characterization of aggresomes (Heath et al., 2001) . Polyclonal anti-PDI serum was generated with bacterially expressed human PDI.
Metabolic labeling of cells, pulse±chase analysis, immunoprecipitation and immunoblotting Cells were detached by trypsin treatment, followed by starvation in methionine-/cysteine-free DME for 45 min at 37°C. Cells were metabolically labeled with 500 mCi/ml of [ 35 S]methionine/cysteine (1200 Ci/mM; NEN-Dupont, Boston, MA) at 37°C for the times indicated. Pulse±chase experiments, cell lysis and immunoprecipitations were performed as described previously (Rehm et al., 2001) . The immunoprecipitates were analyzed by SDS±PAGE followed bȳ uorography (Ploegh, 1995) . aGFP immunoblots were performed with SDS lysates of inhibitor-treated or untreated U373 EGFP±HC and US11 EGFP±HC cells as described (Fiebiger et al., 2001) .
cDNA, transfection and Endo H digestion
The EGFP±HC molecule was cloned with the murine class I molecule H2-K b signal sequence at its N-terminal end and the class I heavy chain HLA-A2 allele (amino acids 25±365) at the C-terminal end. The H2-K b signal sequence directs the chimeric molecule to the ER. The chimeric construct was inserted into pCDNA 3.1 (Invitrogen, Carlsbad, CA) (Swann et al., 2001) . The EGFP±HC construct was transfected into U373-MG, US2 and US11 cells using a liposome-mediated transfection protocol (4 mg of DNA/20 ml of lipofectamine/10 cm dish; Lipofectamine, Gibco, Fredrick, MD). The cytosolic EGFP construct was cloned into pCDNA 3.1 and transfected into U373-MG cells as above. Endo H and N-glycanase (New England Biolabs, Beverly, MA) digestions were performed as described by the manufacturer.
Subcellular fractionation
Subcellular fractionation of metabolically labeled US11 EGFP±HC cells was performed as described (Tortorella et al., 1998 
Flow cytometry analysis
Quantitative¯ow cytometry analysis of accumulation of the green uorescent reporter construct after the inhibition of proteasomal degradation in living cells was performed by FACS (FACS Calibur; Beckton Dickinson, Mountain View, CA) supported by CellQuest software (Beckton Dickinson). Mean¯uorescence intensity correlates to the amount of intracellular EGFP±HC and is monitored under the conditions indicated.
Immunostaining and confocal microscopy
Immuno¯uorescence experiments were performed essentially as described (Driessen et al., 1999) with minor modi®cations. Cells were allowed to attach to slides overnight before inhibitor incubation with [ZL 3 VS (Wiertz et al., 1996b) or the peptide aldehyde inhibitor carboxybenzyl-leucyl-leucyl-leucinal, MG132, (Lee and Goldberg, 1996) ; 50 mM ®nal from a DMSO stock]. DMSO was used as solvent control. Where indicated, protein de novo synthesis was inhibited by the addition of cycloheximide (CHX) (50 mg/ml, ®nal). After ®xation with 3.7% paraformaldehyde for 20 min at room temperature immunohistochemistry was performed in a 0.5% saponin/3% BSA/PBS solution to de®ne the intracellular location of the EGFP±HC fusion protein. Alexa Fluor â 594-conjugated concanavalin A (Molecular Probes, Eugene, OR), anticalnexin (mAb A8) and anti-PDI (polyclonal serum, rabbit anti-human) staining were performed to de®ne ER structures. mAbs W6/32 and HC10 were used to de®ne localization of properly folded and total MHC class I reactivity, respectively. aGFP serum depicts the EGFP moiety. Antimouse Alexa Fluor â 568 (Molecular Probes) and anti-rabbit CyÔ3 (Jackson Laboratory, Bar Harbor, ME) were used as the¯uorescent probe. Further analysis were performed with a Bio-Rad MRC1024 confocal laser scanning microscope. The merge images were analyzed for the presence of EGFP±HC in the ER with the colocalization program from Bio-Rad (Driessen et al., 1999) .
